Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study
Thomson MJ, Serper M, Khungar V, Weiss LM, Trinh H, Firpi-Morell R, Roden M, Loomba R, Barritt AS, Gazis D, Mospan AR, Fried MW, Reddy KR, Lok AS. Prevalence and Factors Associated With Statin Use Among Patients With Nonalcoholic Fatty Liver Disease in the TARGET-NASH Study. Clinical Gastroenterology And Hepatology 2021, 20: 458-460.e4. PMID: 33775894, PMCID: PMC8464616, DOI: 10.1016/j.cgh.2021.03.031.Peer-Reviewed Original ResearchMeSH KeywordsHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLiver CirrhosisLiver NeoplasmsNon-alcoholic Fatty Liver DiseasePrevalenceConceptsNonalcoholic fatty liver diseaseFatty liver diseaseLiver diseaseStatin useReal-world cohortCoenzyme reductase inhibitorsHepatic decompensationCardiovascular eventsPatient factorsCardiovascular diseasePatientsLower mortalityReductase inhibitorsStatinsDiseasePrevalenceRiskDecompensationCarcinomaHepatotoxicityCohortMortality